Centrex Attends Homeland Security Summit.

Business Editors, Health/Medical Writers

TULSA--(BW HealthWire)--June 13, 2002

Centrex, Inc. (OTCBB:CNEX) today announced that the Company's CEO, Thomas R. Coughlin, Jr., M.D., attended the Homeland Security Summit in Washington, D.C. June 6-7, 2002.

The Summit was attended by over 700 delegates from government and industry that were invited to meet at the Reagan Office Building to discuss the future of terrorism threats against the United States.

Sessions at the Summit were separated into three Tracks:

-- Track 1 - Aviation, Transportation and Defense. This Track was sponsored by
Johnson Controls and Lockheed Martin.

-- Track 2 - Business Strategy and Economics. This Track was sponsored by
Sybase and Underwriters Laboratories, Inc.

-- Track 3 - Infrastructure and Natural Resources.

The Summit was produced by Aviation Week, Business Week, McGraw-Hill Construction, Platts and Standard & Poor's and the presenting partner was Teradata, a division of NCR. Several companies exhibited security devices and systems designed to protect the country's infrastructure from terrorist attacks. The devices ranged from communications security for phone systems and computer networks to building key card and personnel ID systems. There was also a great emphasis on devices for monitoring building and airport security, including next generation metal detectors and explosives screening devices.

Even though a bioterrorism attack is considered by both the federal government and private industry to be one of the most serious threats, there were no biological agent detection devices exhibited.

Centrex owns the exclusive worldwide license to develop, manufacture and market a system for detecting microbial contamination in air, food, and water. The detection system, currently in development, is designed to be adaptable and is easily tailored to detect a variety of bacterial or viral organisms by recognizing the unique DNA fingerprint of the organism. Since the September 11th attacks and the subsequent bioterrorism attacks through the U.S. mail, the Company has expanded its mission to include the development of technology for the rapid detection of potential bioterrorism agents. The organisms being considered for detection by the prototype device include all those named in the validated threat list published by the Defense Intelligence Agency, in addition to several other potential biowarfare agents. The proposed device is a simultaneous multi-channel detection system that is compact, fully automated and capable of monitoring the presence of biological agents in air, food and water.

For more information, visit the Centrex website at www.centrexcorporation.com or call Investor Relations at 585/216-2072.

This press release contains some forward-looking statements. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Forward-looking statements in this document should be evaluated together with the many uncertainties that affect our business. Those uncertainties are discussed in the Company's SEC filings.